Technical Data
A2275-60C
Amyloid A, Serum, Human (Serum, Amyloid A, SAA) BioAssay™ ELISA Kit
96Tests
Kits and Assays Storage: 4°C/-20°CShipping: Blue Ice
Amyloid A, Serum, Human (Serum, Amyloid A, SAA) BioAssay™ ELISA Kit is to be used for the in vitro quantitative determination human serum amyloid A (SAA) concentrations in serum, plasma, cell culture supernatant and other biological fluids.

Amyloidosis includes a family of diseases which have in common the extracellular deposition of beta-pleated brillar protein. Amyloidosis associated with chronic in ammatory conditions. (AA-type) and Amyloidosis related to plasma cel dyscrasia (AL-type) are the most common. The frequency of amyloidosis associated with chronic hemodialysis (B2M-type) is growing rapidly.

Sensitivity:
Calibrator Diluent 1: 1.1ng/ml
Calibrator Diluent 2: 0.6ng/ml

Range: 0-80ng/ml

Specificity:
Recognizes both natural and recombinant human SAA. Does no exhibit detectable crossreactivity with human IL-8, IL-1b, MCAF, FGF, TGF-b, EGF, GM-CSF, M-CSF, MCP-3, TNF-a, RANTES and EPO.

Kit Components:
A2275-60C1: SAA microtiter plate, 1 x 96wells
A2275-60C2: SAA conjugate, 1 x 15ml
A2275-60C3: SAA standard, 2 x 160ng
A2275-60C4: Calibator Diluent I, 1 x 30ml
A2275-60C5: Calibator Diluent II, 1 x 30ml
A2275-60C6: Wash buffer (20X), 1 x 60ml
A2275-60C7: Substrate A, 1 x 11ml
A2275-60C8: Substrate B, 1 x 11ml
A2275-60C9: Stop solution, H2SO4, 1 x 14ml

Storage and Stability:
Store *A2275-60C3 at -20°C. Store other components at 4°C. Stable for 6 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
US Biological application references: 1. Viguerie, N. et al., (2012) Physiol. Genomics physiolgenomics.00032.2011 2. Hergenroeder, G. et al., (2008) J. Neurotrauma 25:79-93. 1. Skinner, M., J. Internal Med. 232: 514-523 (1992). 2. Kisilevsky, R., Med. Hypoth. 35(3): 37-41 (1991). 3. Malle, E., et al., Atheroscl. 102: 131-146 (1993). 4. Baussermann, L.L., et al. Eur. J. Clin. Invest. 18: 619-626, (1988). 5. Badolato, R., et al., J. Exp. Med. 180: 203-209 (1994). 6. Xu, L., et al., J. Immunol. 155: 1184-1190 (1995). 7. Liang, J., et al., J. Lipid Res. 36: 37-46 (1995). 8. Knecth, A., et al., Ann. Int. Med. 102(1): 71-72 (1985). 9. Reinoff, J.R., et al., Mol. Bio. Med. 7: 287-298 (1990). 10. Marhaug, G., et al., Acta. Peadiatr. Scand. 72: 861-866(1983). 11. Casl, M.T., et al., Nephron. 70: 112-113 (1995). 12. Casl, M.T., et al., Ann. Clin. Biochem. 30: 272-277 (1993). 13. Husebekk, A., et al., Scand. J. Infec. Dis. 18: 389-394 (1986). 14. Nakayama, T., et al., Clin. Chem. 39(2): 293-297 (1993). 15. Honkanen, E., et al., Nephron. 57: 283-287 (1991). 16. Hiroyuki, M., et al., Arch. Dis. Child. 68: 210-214 (1993). 17. Thomson, D., et al., Ann. Clin. Biochem. 29: 123-131 (1992). 18. Luizzo, G., et al., N. Eng. J. Med. 331: 417-424 (1994). 19. Casl, M.T., et al., Ann. Clin. Biochem. 32: 196-200 (1995).

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.